Top Markets
#1 Nesa Nesa +721.69%
#2 Merlin's Seal BTC Merlin's Seal BTC +45.58%
#3 EXOD EXOD +22.78%
#4 Pons Pons +16.93%
#5 Prom Prom +12.59%
#6 Venom Venom +10.85%
#7 MetaDAO MetaDAO +9.76%
#8 PondCoin PondCoin +8.89%
#9 Cash Cat Cash Cat +8.58%
#10 Fartcoin Fartcoin +8.35%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Classement en actions #19722
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Prix de l'action
$2.42
Dernière synchronisation: 2026-08-25
Capitalisation boursière
$152.37M
Changement (1 jour)
5.22%
Changement (1 an)
39.88%
Pays
US
Échange Connect Biopharma Holdings Limited (CNTB)

Catégorie

Healthcare
Bénéfices pour Connect Biopharma Holdings Limited (CNTB)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Connect Biopharma Holdings Limited, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Connect Biopharma Holdings Limited de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH